UNSPSC 51113206: Thiotepa

This classification denotes an ethylenimine compound with the molecular formula C6H12N3PS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 905Z5W3GKH, chemically known as 1,1,1-phosphinothioylidynetrisaziridine but more generally known as thiotepa, which bears US NIH Compound Identifier 5453. European Medicines Agency schedules Thiotepa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10985MIG.

UNSPSC 51113206 Thiotepa is a Commodity code representing a specific chemotherapy agent procured by state health agencies through their pharmacy benefit programs and prescription fulfillment channels. State and local governments source this drug primarily through health and human services departments that manage Medicaid, employee health plans, and correctional-facility pharmacy operations. The solicitations under this code typically involve procurement of the pharmaceutical itself, often bundled within broader pharmacy benefit management initiatives, direct-to-manufacturer contracting arrangements, or group purchasing organization agreements that aim to manage drug costs and improve supply-chain efficiency.

The Texas Health and Human Services Commission issued Request for Information HHS0017013 in late March 2026, with a response deadline of April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI sought information from vendors and stakeholders about implementing direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment efficiency and cost management. The state specifically requested vendor experience with direct contracting for self-insured employers and health plans in both private and government sectors within the past two years, flexibility to negotiate contracts based on negotiated net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. Texas represents the primary recent activity identified under this code; no other state or local jurisdictions posted solicitations for Thiotepa during the review period.